Hong Kong-based private equity firm Templewater has acquired Singaporean healthcare provider Ascensus Health Group (AHG) from Dymon Asia, according to an announcement. Financial details of the transaction were not disclosed.
Initially called Singapore O&G, Ascensus Health Group was founded in 2011 by medical professionals specialising in obstetrics & gynaecology. It operates a network of 13 clinics across Singapore and Malaysia, providing services spanning paediatrics, dermatology, fertility, and related disciplines, supported by a team of more than 60 medical and clinical staff.
Formerly listed on the Singapore Exchange, Ascensus was taken private in 2022 through a privatisation deal backed by Dymon Asia. The deal was executed via a special purpose vehicle, NewMedCo Group, which acquired the healthcare provider at a valuation of about S$200 million.
Following the privatisation, the company rebranded from Singapore O&G to Ascensus Health Group as it expanded beyond obstetrics & gynaecology into a broader multi-speciality healthcare platform.
Templewater has been expanding its healthcare presence over the last few months. In March 2026, it acquired The Women’s Clinic Group (TWCG), one of Hong Kong’s largest private women’s healthcare specialist groups. The platform operates six clinics, three IVF laboratories, and one blood laboratory across Hong Kong and Singapore, employing 150 staff to provide fertility, O&G, and traditional Chinese medicine services.
The latest transaction underscores Templewater’s strategy to consolidate fragmented specialist healthcare services in Asia, particularly within women’s health—a segment seeing rising investor interest amid growing healthcare awareness, ageing demographics, delayed parenthood, and increasing demand for specialised fertility and reproductive care.
“Women’s health remains an underserved and rapidly evolving segment across Asia,” Templewater said in a statement, adding that it plans to work closely with Ascensus Health’s doctors, management team, and staff to support the company’s next phase of growth.
The deal also reflects a broader trend of private capital flowing into healthcare services and specialist medical platforms across Southeast Asia, where investors are increasingly targeting niche healthcare verticals instead of large general hospitals.
In Singapore, specialist healthcare platforms and day surgery operators continue to attract investor interest due to their asset-light models, recurring demand and strong margins, particularly across fertility, oncology, ophthalmology and dialysis. However, scaling healthcare assets across Southeast Asia remains challenging because of regulatory complexity, physician retention risks and fragmented reimbursement systems. Rising operating costs and shortages of trained healthcare professionals are also pressuring margins across the region.
In another deal in the healthcare sector by Templewater, the PE firm acquired Luye Medical Group’s oncology and cardiology businesses in Singapore in October 2023.
Dymon Asia, meanwhile, has been attempting to sell some of its underlying assets in recent times. The mid-market fund was most recently slated to make an early exit from the hotels group Amara Holdings, a portfolio of its 2022-vintage third fund. In another development, Deutsche Bank was hired for the sale process of Singaporean tool maker Meiban, an investment from Dymon Asia’s 2017-vintage second fund, DealStreetAsia reported.
More recently, Dymon Asia, divested its entire holding in the Singapore-based operator of Texas Chicken, Select Group, to a vehicle linked to the Tan family that founded the company in 1991. The PE firm fully exited Select after about nine years of being its shareholder.
